Insmed Incorporated (NASDAQ:INSM) CFO Sells $67,925.52 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the completion of the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $7,573,950.36. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The stock was sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Performance

NASDAQ:INSM opened at $65.25 on Friday. The company has a fifty day moving average of $71.23 and a two-hundred day moving average of $72.42. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The stock has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the previous year, the company earned ($1.10) earnings per share. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. As a group, research analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in Insmed during the 3rd quarter worth $30,000. GAMMA Investing LLC lifted its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the last quarter. Blue Trust Inc. grew its stake in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. acquired a new stake in Insmed in the 3rd quarter valued at about $133,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on INSM. JPMorgan Chase & Co. raised their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America upped their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.